BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced a strategic collaboration with Moonlight Bio, Inc., a Seattle-based biotechnology company, to develop next-generation cell therapies targeting difficult-to-treat cancers.
Under the agreement, Biocytogen will provide access to its off-the-shelf library of fully human antibody binders against therapeutic targets, while Moonlight Bio will lead preclinical development of the cell therapies.
The companies said the partnership is designed to combine Biocytogen’s antibody discovery platforms with Moonlight Bio’s cell therapy capabilities to accelerate the development of new treatments for cancers that are resistant to existing therapies.
“We are thrilled to partner with Moonlight Bio, a pioneering leader in advanced cell therapies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This strategic collaboration leverages our proprietary off-the-shelf fully human antibody library to accelerate the development of cutting-edge cell therapies for difficult-to-treat cancers. It also demonstrates the versatility and broad applicability of Biocytogen’s antibody discovery platforms beyond traditional drug modalities. By combining our expertise, we are poised to accelerate the development of transformative cell therapies that could overcome resistance and offer new hope to patients battling the toughest cancers.”
Biocytogen said its platform integrates gene editing technologies with a fully human antibody library and a portfolio of target-humanized mouse models to support drug discovery and development.
The company has developed its RenMice platforms, including RenMab, RenLite, RenNano, RenTCR, and RenTCR mimic, to enable discovery of monoclonal, bispecific, and multispecific antibodies, as well as antibody-drug conjugates and TCR-mimic antibodies. Through its RenSuper Biologics initiative, Biocytogen offers a library of more than one million fully human antibody sequences targeting over 1,000 proteins for global collaboration.
As of the end of 2025, the company reported more than 350 global agreements spanning co-development, out-licensing, and asset transfers with pharmaceutical and biotechnology partners.
Biocytogen also provides preclinical research tools through its BioMice platform, which includes a large portfolio of humanized animal and cell models, along with pharmacology and gene-editing services. The company is headquartered in Beijing and operates across multiple sites in China, the U.S., and Germany.
